In a bold move, the Trump administration is sending out 100 cease-and-desist letters to drug companies, aiming to eliminate misleading ads. This crackdown includes increased transparency about drug risks and closing loopholes that conceal vital safety information.
In a landmark decision, the Trump administration vows to overhaul the regulations on prescription drug advertising. This move aims to ensure consumers receive accurate information about the risks and benefits of medications, combatting misleading ads that favor expensive drugs over affordable generics.
